PARIS (Reuters) – France on Thursday called on 25,000 adult volunteers to enroll in a series of large-scale clinical trials aimed at assessing the safety and efficacy of several COVID-19 vaccine candidates.
Phase II and III trials, which could begin as early as this month, will take place in 24 hospitals across the country. Volunteers are encouraged to register online.
There is currently no internationally approved vaccine to prevent COVID-19, the disease caused by the novel coronavirus, which has killed more than a million people worldwide.
The French public research organization Inserm, in charge of the project, did not name the vaccines that would be evaluated and said it was currently in discussions with the drug manufacturers, adding that it would choose the candidates “the most promising ”for testing.
More than 150 potential vaccines are in development around the world and tested to stop the COVID-19 pandemic, including 38 in human trials, according to the World Health Organization (WHO).